Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?

Bibliography

• Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet (2000) 355:1158-1159.
   PubMed Web of Science ®Google Scholar
• PALELLA FJ, Jr., DELANEY KM, MOORMAN AC et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl. J. Med. (1998) 338:853-860.
   PubMed Web of Science ®Google Scholar
• MOCROFT A, YOULE M, MOORE A et al.: Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. Aids (2001) 15:185-194.
   PubMed Web of Science ®Google Scholar
• GLASS TR, DE GEEST S, WEBER R et al.: Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J. Acquir. Immune Defic. Syndr. (2006) 41:385-392.
   PubMed Web of Science ®Google Scholar
• BOYLE BA PB, HENNE J, SHEFFIELD S: Patients prefer simplified and well tolerated antiretroviral regimens. In: 15th International AIDS Conference. Bangkok, Thailand (2005).
   Google Scholar
• HAMMER SM, SAAG MS, SCHECHTER M et al.: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 296:827-843.
   PubMed Web of Science ®Google Scholar
• GALLANT JE, DEJESUS E, ARRIBAS JR et al.: Tenofovir DF, emtricitabine, and efavirenz versus zidovudine, lamivudine, and efavirenz for HIV. N Engl. J. Med. (2006) 354:251-60.
   PubMed Web of Science ®Google Scholar
• GALLANT JE, STASZEWSKI S, POZNIAK AL et al.: Efficacy and safety of tenofovir DF versus stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA (2004) 292:191-201.
   PubMed Web of Science ®Google Scholar
• STASZEWSKI S, MORALES-RAMIREZ J, TASHIMA KT et al.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl. J. Med. (1999) 341:1865-1873.
   PubMed Web of Science ®Google Scholar
• YOUNG SD, BRITCHER SF, TRAN LO et al.: L-743, 726(DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus Type 1 reverse transcriptase. Antimicrob. Agents Chemother. (1995) 39:2602-2605.
   PubMed Web of Science ®Google Scholar
• WITVROUW M, PANNECOUQUE C, SWITZER WM, FOLKS TM, DE CLERCQ E, HENEINE W: Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir. Ther. (2004) 9:57-65.
   PubMed Web of Science ®Google Scholar
• WANG LH, BEGLEY J, ST CLAIRE RL III, HARRIS J, WAKEFORD C , ROUSSEAU FS: Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res. Hum. Retroviruses (2004) 20:1173-1182.
   Google Scholar
• ROBBINS BL, SRINIVAS RV, KIM C, BISCHOFBERGER N, FRIDLAND A: Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob. Agents Chemother. (1998) 42:612-617.
   PubMed Web of Science ®Google Scholar
• MATHIAS A PA, SKILLINGTON J, HUI J, HINKLE J, YALE K, KEARNEY BP: Bioequivalence of efavirenz/emtricitabine/tenofovir DF single tablet regimen. In: 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, Portugal (2006).
   Google Scholar
• RIBAUDO HJ, HAAS DW, TIERNEY C et al.: Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin. Infect. Dis. (2006) 42:401-407.
   PubMed Web of Science ®Google Scholar
• DICENZO R, FORREST A, SQUIRES KE et al.: Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. (2003) 47:1929-1935.
   PubMed Web of Science ®Google Scholar
• VELDKAMP AI, HARRIS M, MONTANER JS et al.: The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus Type 1-infected persons. J. Infect. Dis. (2001) 184:37-42.
   PubMed Web of Science ®Google Scholar
• MOLINA JM, PEYTAVIN G, PERUSAT S et al.: Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial). HIV Med. (2004) 5:99-104.
   PubMedGoogle Scholar
• CHITTICK GE, ZONG J, BLUM MR et al.: Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state. Antimicrob. Agents Chemother. (2006) 50:1304-1310.
   PubMed Web of Science ®Google Scholar
• PRUVOST A, NEGREDO E, BENECH H et al.: Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (2005) 49:1907-1914.
   PubMed Web of Science ®Google Scholar
• STARR SE, FLETCHER CV, SPECTOR SA et al.: Efavirenz liquid formulation in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. (2002) 21:659-663.
   PubMed Web of Science ®Google Scholar
• STARR SE, FLETCHER CV, SPECTOR SA et al.: Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus Type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl. J. Med. (1999) 341:1874-1881.
   PubMed Web of Science ®Google Scholar
• WANG LH, WIZNIA AA, RATHORE MH et al.: Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children. Antimicrob. Agents Chemother. (2004) 48:183-191.
   PubMed Web of Science ®Google Scholar
• HAZRA R, BALIS FM, TULLIO AN et al.: Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Antimicrob. Agents Chemother. (2004) 48:124-129.
   PubMed Web of Science ®Google Scholar
• VAN LETH F, PHANUPHAK P, RUXRUNGTHAM K et al.: Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet (2004) 363:1253-1263.
   PubMedGoogle Scholar
• MANOSUTHI W, SUNGKANUPARPH S, VIBHAGOOL A, RATTANASIRI S, THAKKINSTIAN A: Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naive patients with advanced HIV infection. HIV Med. (2004) 5:105-109.
   PubMed Web of Science ®Google Scholar
• COZZI-LEPRI A, PHILLIPS AN, D’ARMINIO MONFORTE A et al.: Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. J. Infect. Dis. (2002) 185:1062-1069.
   PubMedGoogle Scholar
• MANFREDI R, CALZA L, CHIODO F: Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. J. Acquir. Immune Defic. Syndr. (2004) 35:492-502.
   PubMed Web of Science ®Google Scholar
• KEISER P, NASSAR N, WHITE C, KOEN G, MORENO S: Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin. Trials (2002) 3:296-303.
   Google Scholar
• SANNE I, PILIERO P, SQUIRES K, THIRY A, SCHNITTMAN S: Results of a Phase II clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J. Acquir. Immune. Defic. Syndr. (2003) 32:18-29.
   PubMed Web of Science ®Google Scholar
• JOHNSON M, GRINSZTEJN B, RODRIGUEZ C et al.: 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. Aids (2006) 20:711-718.
   PubMed Web of Science ®Google Scholar
• GONG YF, ROBINSON BS, ROSE RE et al.: In vitro resistance profile of the human immunodeficiency virus Type 1 protease inhibitor BMS-232632. Antimicrob. Agents Chemother. (2000) 44:2319-2326.
   PubMed Web of Science ®Google Scholar
• SQUIRES K, LAZZARIN A, GATELL JM et al.: Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J. Acquir. Immune Defic. Syndr. (2004) 36:1011-1019.
   PubMed Web of Science ®Google Scholar
• MANFREDI R, CALZA L, CHIODO F. First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients. Aids (2004) 18:2331-2333.
   PubMed Web of Science ®Google Scholar
• PANAGOPOULOS P, TSIODRAS S, ANTONIADOU A et al.: Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors. Clin. Microbiol. Infect. (2006) 12:486-489.
   Google Scholar
• TORTI C, MAGGIOLO F, PATRONI A et al.: Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort. J. Antimicrob. Chemother. (2005) 56:190-195.
   Google Scholar
• RIDDLER SA, HAUBRICH R, DIRIENZO G et al.: A prospective, randomized, Phase III trial of NRTI-, PI-, NNRTI-sparing regimens for initial treatment of HIV-1 infection – ACTG 5142. In: 16th International AIDS Conference. Toronto, Canada (2006).
   Google Scholar
• BARTLETT JA, JOHNSON J, HERRERA G, SOSA N, RODRIGUEZ AE, MS S: Abacavir/Lamivudine (ABC/3TC) in combination with Efavirenz (NNRTI), Amprenavir/Ritonavir (PI) or Stavudine (NRTI): ESS40001 (CLASS) Preliminary 48-week results. In: 15th International AIDS Conference. Bangkok, Thailand (2004).
   Google Scholar
• MONTANER JS, SCHUTZ M, SCHWARTZ R et al.: Efficacy, Safety and Pharmacokinetics of Once-Daily Saquinavir Soft-Gelatin Capsule/Ritonavir in Antiretroviral-Naive, HIV-Infected Patients. MedGenMed (2006) 8:36.
   PubMedGoogle Scholar
• BENSON CA, VAN DER HORST C, LAMARCA A et al.: A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. Aids (2004) 18:2269-2276.
   PubMedGoogle Scholar
• SAAG MS, CAHN P, RAFFI F et al.: Efficacy and safety of emtricitabine versus stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA (2004) 292:180-189.
   PubMed Web of Science ®Google Scholar
• POZNIAK AL, GALLANT JE, DEJESUS E et al.: Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and Morphologic Changes-A 96-Week Analysis. J. Acquir. Immune Defic. Syndr. (2006) 43:535-540.
   PubMed Web of Science ®Google Scholar
• PILIERO PJ: Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J. Acquir. Immune Defic. Syndr. (2004) 37 (Suppl. 1):S2-S12.
   PubMed Web of Science ®Google Scholar
• KHANLOU H, YEH V, GUYER B AND FARTHING C: Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. AIDS Patient Care STDS (2005) 19:135-140.
   PubMed Web of Science ®Google Scholar
• LANDMAN R, DESCAMPS D, PEYTAVIN G et al.: Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study. HIV Clin. Trials (2005) 6:291-301.
   PubMedGoogle Scholar
• JEMSEK J H, HARPER E: Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients recieving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA (2004).
   Google Scholar
• GULICK RM, RIBAUDO HJ, SHIKUMA CM et al.: Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl. J. Med. (2004) 350:1850-1861.
   PubMed Web of Science ®Google Scholar
• LEON A, MARTINEZ E, MALLOLAS J et al.: Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine. Aids (2005) 19:213-215.
   PubMed Web of Science ®Google Scholar
• PODZAMCZER D, FERRER E, GATELL JM et al.: Early virological failure with a combination of tenofovir, didanosine and efavirenz. Antivir. Ther. (2005) 10:171-7.
   PubMed Web of Science ®Google Scholar
• VAN LUZEN J SK, KUHLMANN B et al.: High rate of virological failure during once daily therapy with tenofovir+didanosine 250 mg+efavirenz in antiretroviral naive patients – results of the 12 week interim analysis of the TEDDI trial. In: Presented at the 3rd International AIDS Society Conference on HIV Treatment and Pathogenesis. Rio de Janiero, Brazil (2005).
   Google Scholar
• MOYLE G, HAND J, MANDALIA S, NELSON M, GAZZARD B: Early virological failure in persons with viral loads > 100,000cps/ml and CD4 counts < 200mm3 receiving ddI/Tenofovir/Efavirenz as initial therapy: Results from a randomised comparative trial. In: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., USA (2004).
   Google Scholar
• MOYLE G: Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. Antivir. Ther. (2005) 10 (Suppl. 2):M47-M52.
   PubMedGoogle Scholar
• BRINKMAN K, TER HOFSTEDE HJ, BURGER DM, SMEITINK JA, KOOPMANS PP: Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. Aids (1998) 12:1735-1744.
   PubMed Web of Science ®Google Scholar
• MARTIN JL, BROWN CE, MATTHEWS-DAVIS N, REARDON JE: Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob. Agents Chemother. (1994) 38:2743-2749.
   PubMed Web of Science ®Google Scholar
• NOLAN D, HAMMOND E, JAMES I, MCKINNON E, MALLAL S: Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir. Ther. (2003) 8:617-626.
   PubMed Web of Science ®Google Scholar
• REISS P, CASULA M, DE RONDE A, WEVERLING GJ, GOUDSMIT J, LANGE JM: Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) versus single (zidovudine) nucleoside reverse transcriptase inhibitors. HIV Med. (2004) 5:11-14.
   PubMed Web of Science ®Google Scholar
• HOY JF, GAHAN ME, CARR A et al.: Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir. J. Infect. Dis. (2004) 190:688-692.
   PubMed Web of Science ®Google Scholar
• BIRKUS G, HITCHCOCK MJ, CIHLAR T: Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. (2002) 46:716-723.
   PubMed Web of Science ®Google Scholar
• FENG JY, MURAKAMI E, ZORCA SM et al.: Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2’,3’-dideoxy-5-fluoro-3’-thiacytidine-triphosphate analogs by human immunodeficiency virus Type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob. Agents Chemother. (2004) 48:1300-1306.
   PubMed Web of Science ®Google Scholar
• IZZEDINE H, ISNARD-BAGNIS C, HULOT JS et al.: Renal safety of tenofovir in HIV treatment-experienced patients. Aids (2004) 18:1074-1076.
   PubMed Web of Science ®Google Scholar
• MALIK A, ABRAHAM , MALIK N: Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review of literature. J. Infect. (2005) 51:E61-E65.
   PubMedGoogle Scholar
• PEYRIERE H, REYNES J, ROUANET I et al.: Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J. Acquir. Immune. Defic. Syndr. (2004) 35:269-273.
   PubMed Web of Science ®Google Scholar
• THOMPSON MA, HAUBRICH R, MARGOLIS D et al.: Differences in calculated glomerular filtration rates in efavirenz- or tenofovir-treated adults in ESS40006. In: 13th Conference on Retroviruses and Opportunistic Infections. Colorado, USA (2006).
   Google Scholar
• IZZEDINE H, HULOT JS, VITTECOQ D et al.: Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol. Dial. Transplant (2005) 20:743-746.
   Google Scholar
• GALLANT JE, PARISH MA, KERULY JC, MOORE RD: Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin. Infect. Dis. (2005) 40:1194-1198.
   PubMed Web of Science ®Google Scholar
• COCKCROFT DW, GAULT MH: Prediction of creatinine clearance from serum creatinine. Nephron (1976) 16:31-41
   PubMed Web of Science ®Google Scholar
• SHEMESH O, GOLBETZ H, KRISS JP, MYERS BD: Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. (1985) 28:830-838.
   PubMed Web of Science ®Google Scholar
• GUTMANN H, FRICKER G, DREWE J, TOEROEK M, MILLER DS: Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol. Pharmacol. (1999) 56:383-389.
   Google Scholar
• MALLANTS R, VAN OOSTERWYCK K, VAN VAECK L, MOLS R, DE CLERCQ E, AUGUSTIJNS P: Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica (2005) 35:1055-66.
   PubMed Web of Science ®Google Scholar
• IZZEDINE H, LAUNAY-VACHER V, DERAY G: Renal tubular transporters and antiviral drugs: an update. Aids (2005) 19:455-462.
   PubMed Web of Science ®Google Scholar
• LOUIE S LJ, NEELY M, BERINGER P: Multidrug resistance protein-2 (MRP2) inhibition by ritonavir (RTV) increases tenofovir (TFV)-associated cytotoxicity In: 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec, Canada (2005).
   Google Scholar
• RAY AS, CIHLAR T, ROBINSON KL et al.: Mechanism of active renal tubular efflux of tenofovir. Antimicrob. Agents Chemother. (2006) 50:3297-3304.
   PubMed Web of Science ®Google Scholar
• BICKEL M, STEPHAN C, ROTTMANN C et al.: Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis. Scand J. Infect. Dis. (2005) 37:520-522.
   Google Scholar
• GUTIERREZ F, NAVARRO A, PADILLA S et al.: Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin. Infect. Dis. (2005) 41:1648-1653.
   PubMed Web of Science ®Google Scholar
• MARZOLINI C, TELENTI A, DECOSTERD LA, GREUB G, BIOLLAZ J, BUCLIN T: Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. Aids (2001) 15:71-75.
   PubMed Web of Science ®Google Scholar
• KAPPELHOFF BS, VAN LETH F, ROBINSON PA et al.: Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir. Ther. (2005) 10:489-498.
   PubMed Web of Science ®Google Scholar
• CESPEDES MS, ABERG JA: Neuropsychiatric complications of antiretroviral therapy. Drug Saf. (2006) 29:865-74.
   PubMed Web of Science ®Google Scholar
• CLAVEL F, HANCE AJ: HIV drug resistance. N Engl. J. Med. (2004) 350:1023-1035.
   PubMed Web of Science ®Google Scholar
• BODEN D, HURLEY A, ZHANG L et al.: HIV-1 drug resistance in newly infected individuals. JAMA (1999) 282:1135-1141.
   PubMed Web of Science ®Google Scholar
• LITTLE SJ, HOLTE S, ROUTY JP et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl. J. Med. (2002) 347:385-394.
   PubMed Web of Science ®Google Scholar
• SHET A, BERRY L, MOHRI H et al.: Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J. Acquir. Immune Defic. Syndr. (2006) 41:439-446.
   PubMed Web of Science ®Google Scholar
• CHARPENTIER C, DWYER DE, MAMMANO F, LECOSSIER D, CLAVEL F, HANCE AJ: Role of minority populations of human immunodeficiency virus Type 1 in the evolution of viral resistance to protease inhibitors. J. Virol. (2004) 78:4234-4247.
   Google Scholar
• LITTLE SJ KK, IGNACIO CC, WONG, JK, LIE Y, FROST S, RICHMAN DD: Persistence of transmitted drug-resistant virus among subjects with primary HIV infection deferring antiretroviral therapy. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA (2004).
   Google Scholar
• LAURENCE J: Once-daily dosing and the treatment of HIV disease. AIDS Read (2006) 16:444-445.
   PubMedGoogle Scholar
• MURRI R, MARCOTULLIO S, LUPOLI P, VON SCHLOESSER F: Is ‘once-daily’ regimen a key strategy for improving adherence to antiretroviral regimens? J. Acquir. Immune Defic. Syndr. (2006) 42:259-260.
   PubMedGoogle Scholar
• KATZENSTEIN DA, BOSCH RJ, HELLMANN N, WANG N, BACHELER L AND ALBRECHT MA: Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. Aids (2003) 17:821-830.
   PubMed Web of Science ®Google Scholar